The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation

Pharmacogenetics

Volumn 9, Issue 1, 1999, Pages 43-53

  Gill, Helen J ^a   Tjia, John F ^a   Kitteringham, Neil R ^a   Pirmohamed, Munir ^a   Back, David J ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

CYP2C9; Genetic polymorphism; Metabolism; Sulphamethoxazole

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; HYDROXYLAMINE; SULFAMETHOXAZOLE; SULFONAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG CLEARANCE; DRUG HYDROXYLATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER; MICROSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

TRIXIS;

EID: 0032917169     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199902000-00007     Document Type: Article

References (58)

1. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier J-C, Corcos L, Turlin B, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44:707-715.
2. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1992; 5:1237-1257.
3. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32:210-241.
4. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7:51-58.
5. Bingham PM, Levis R, Rubin GM. Cloning DNA sequences from the white locus of Drosophila-melanogaster by a novel and general method. Cell 1981; 25:693-704.
6. Carr A, Tindall B, Penny R, Cooper DA. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol 1993; 94:21-25.
7. Carr A, Cooper DA. Pathogenesis and management of HIV-associated drug hypersensitivity. AIDS Clin Rev 1995; 96:65-97.
8. 359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997; 7:211-221.
9. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7:203-210.
10. Cribb AE, Miller M, Leeder JS, Hill J, Spielberg SP. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione: implications for idiosyncratic toxicity. Drug Metab Dispos 1991; 19:900-906.
11. 4-Hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P450 2C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995; 23:406-414.
12. Cribb AE, Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adv Drug React Toxicol Rev 1996; 15:9-50.
13. Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med 1995; 73:539-553.
14. Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LM, McManus ME. Relationship between phenytoin and tolbulamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991; 31:125-130.
15. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effects on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5:389-392.
16. Gill HJ, Tingle MD, Park BK. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 1995; 40:531-538.
17. Gill HJ, Maggs JL, Madden S, Pirmohamed M, Park BK. The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. Br J Clin Pharmacol 1996; 42:347-353.
18. Gill HJ, Hough SJ, Naisbitt DJ, Maggs JL, Kitteringham NR, Pirmohamed M, Park BK. The relationship between the disposition and immunogenicity of sulphamethoxazole in the rat. J Pharmacol Exp Ther 1997; 282:795-801.
19. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100:495-499.
20. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992; 267:83-90.
21. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baclovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and 1359 L mutant forms. Arch Biochem Biophys 1996; 333:447-458.
22. Hoover DR, Sahh A, Bacellar H, Phair J, Detels R, Anderson R, Kaslow RA. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med 1993; 329:1922-1926.
23. Inaba T. Phenytoin: pharmacogenetic polymorphism of 4′-hydroxylation. Pharmacol Ther 1990; 46:341-347.
24. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 1997; 7:103-113.
25. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalised patients. Rev Infect Dis 1982; 4:426-428.
26. Jung AC, Paauw DS. Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch Intern Med 1994; 154:2402-2406.
27. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1993; 43:234-239.
28. Lawson DH, Paice BJ. Adverse reactions to trimethoprim-sulfamethoxazole. Rev Infect Dis 1982; 4:429-433.
29. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53:529-535.
30. Leeman T, Transon C, Bonnabry P, Dayer P. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 1993; 19:189-195.
31. London SJ, Daly AK, Leathart JBS, Navidi WC, Idle JR. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 1996; 6:527-533.
32. London SJ, Sullivan-Klose T, Daly AK, Idle JR. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics 1997; 7:401-404.
33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-275.
34. Naisbitt DJ, O'Neill PM, Pirmohamed M, Park BK. Synthesis and reactions of nitroso sulphamethoxazole with biological nucleophiles: implications for immune mediated toxicity. Bioorg Med Chem Let 1996; 6:1511-1516.
35. Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes. J Biol Chem 1964; 239:2370-2378.
36. Page MA, Boutagy JS, Shenfield GM. A screening test for slow metabolisers of tolbutamide. Br J Clin Pharmacol 1991; 31:649-654.
37. Parkinson A. Biotransformation of xenobiotics. In: Klaassen CD, editor. Casarett and Doull's toxicology: the basic science of poisons, 5th edn. New York: McGraw-Hill; 1996. pp. 154.
38. Pirmohamed M, Park BK. Drug reactions in HIV-infected patients. Postgrad Doctor 1995; 18:438-444.
39. Pirmohamed M, Williams D, Tingle MD, Barry M, Khoo S, O'Mahony C. et al. Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency. AIDS 1996; 10:501-507.
40. Piscitelli SC, Reiss WG, Eigg WD, Petros WP. Pharmacokinetic studies with recombinant cytokines. Clin Pharmacokinet 1997:32:368-381.
41. Rettie AE, Korzekwa R, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-450 2C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5:54-59.
42. Rettie A, Wienkers LC, Gonzalez FJ, Tragger WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4:39-42.
43. Richardson TH, Johnson EF. The CYP2C9 subfamily. In: Ioannides C, editor. Cytochromes P450. Metabolic and toxicological aspects. Boca Raton: CRC Press; 1996. pp. 161-182.
44. Rieder MJ, Uetrecht J, Shear NH, Spielberg SP. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther 1988; 244:724-728.
45. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991;49:13-17.
46. Rieder MJ, Krause R, Bird IA. Time-course of toxicity of reactive sulfonamide metabolites. Toxicology 1995; 95:141-146.
47. Scott J, Poffenbarger PL. Pharmacogenetics of tolbulamide metabolism in humans. Diabetes 1979; 28:41-51.
48. Shear NH, Spielberg SP. Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105:179-184.
49. Spielberg S, McCrea J, Cribb A, Rushmore T, Waldman S, Bjornsson T, et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther 1996; 59:215.
50. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361-367.
51. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6:429-439.
52. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-349.
53. Transon C, Lecoeur S, Leemann T, Beaune P, Dayer P. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur J Clin Pharmacol 1996; 51:79-85.
54. Vasko MR, Bell RD, Daly DD, Pippenger CE. Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther 1980; 27:96-103.
55. Vermeij P, Ferrari MD, Buruma OJ. Veenema H, de Wolf FA. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family. Clin Pharmacol Ther 1988; 44:588-593.
56. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Rees DLP, Gasser R, et al. Site directed mutation studies of human liver cytochrome P-450 isozymes in the CYP2C subfamily. Biochem J 1993; 289:533-538.
57. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Beaune P, Bagot M. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5:255-258.
58. Yamazaki H, Inoue K, Shimada T. Roles of two allelic variants (Arg144Cys and He359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 1998; 28:103-115.